Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 55,843	$ 96,363
Short-term investments	900,163	1,228,499
Accounts receivable	42,925	36,802
Inventory	12,892	12,665
Advance payments to contract manufacturers	10,483	31,834
Other current assets	21,550	15,387
Total current assets	1,043,856	1,421,550
Long-term investments	197,715	279,119
Property, plant and equipment, net	60,189	65,665
Operating lease right-of-use assets	128,985	134,177
Goodwill	76,501	76,501
Other assets	1,420	344
Total assets	1,508,666	1,977,356
Current liabilities:
Senior secured notes, net and interest payable (see Note 1)	0	252,891
Accounts payable	15,484	19,234
Accrued compensation	29,504	11,467
Accrued clinical trial expenses	48,886	32,626
Accrued contract manufacturing expenses	7,141	7,304
Other accrued expenses	9,630	12,338
Operating lease liabilities, current portion	15,348	12,516
Deferred revenue, current portion	507	5,517
Total current liabilities	126,500	353,893
Operating lease liabilities, less current portion	139,022	142,730
Liability related to the sale of future royalties, net	66,378	72,020
Deferred revenue, less current portion	2,494	2,554
Other long-term liabilities	3,291	768
Total liabilities	337,685	571,965
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2020 or December 31, 2019	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 179,394 shares and 176,505 shares outstanding at September 30, 2020 and December 31, 2019, respectively	18	17
Capital in excess of par value	3,363,998	3,271,097
Accumulated other comprehensive income (loss)	(1,080)	(1,005)
Accumulated deficit	(2,191,955)	(1,864,718)
Total stockholders’ equity	1,170,981	1,405,391
Total liabilities and stockholders’ equity	$ 1,508,666	$ 1,977,356